Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer

PURPOSE: S-trans,trans-Farnesylthiosalicylic Acid (FTS, salirasib) inhibits Ras-dependent cell growth by dislodging all isoforms of Ras, including mutant Ras, from the plasma membrane. This study evaluated the activity, safety, and toxicity of salirasib in preclinical models and patients with metast...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Laheru, Daniel, Shah, Preeti, Rajeshkumar, N. V., McAllister, Florencia, Taylor, Gretchen, Goldsweig, Howard, Le, Dung T., Donehower, Ross, Jimeno, Antonio, Linden, Sheila, Zhao, Ming, Song, Dongweon, Rudek, Michelle A., Hidalgo, Manuel
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2012
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3557459/
https://ncbi.nlm.nih.gov/pubmed/22547163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-012-9818-6
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge